Key Takeaways NVO won FDA approval for oral Wegovy, the first GLP-1 RA pill for weight management and CV risk reduction.NVO's oral Wegovy matched injectable efficacy with similar safety and easier dosing that may boost adherence.First-mover oral launch could help NVO regain share from LLY and boost Wegovy sales after 2025 slowdown.Last month, Novo Nordisk (NVO) announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the ...